YRD Investors Have Opportunity to Join Yiren Digital Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$YRD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PODD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater... Read more.
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater... Read more.
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe... Read more.
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated... Read more.
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16,... Read more.
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its... Read more.